Table 1.
Patient Characteristics
| Variable | RT1 (n = 92) | RT2 (n = 108) |
|---|---|---|
| Mean age, years | 67.4 | 67.7 |
| Gender, n (%) | ||
| Male | 72 (78.3) | 69 (63.9) |
| Female | 20 (21.7) | 39 (36.1) |
| WHO performance status, n (%) | ||
| 0–1 | 80 (87) | 85 (78.7) |
| ≥2 | 12 (13) | 23 (21.3) |
| TNM stage, n (%) | ||
| I | 12 (13) | 18 (16.7) |
| II | 9 (9.8) | 8 (0.1) |
| IIIA | 29 (31.5) | 24 (22.2) |
| IIIB | 42 (45.7) | 56 (51.9) |
| Missing | 2 (0.0) | |
| Mean gross tumor volume, cc3 | 86.8 | 61.7 |
| N stage, n (%) | ||
| 0–1 | 38 (41.3) | 46 (42.6) |
| ≥2 | 54 (58.7) | 62 (57.4) |
| Chemotherapy, n (%) | 61 (66.3) | 73 (67.6) |
| Histological subtype, n (%) | ||
| Adenocarcinoma | 13 (14.1) | 10 (9.3) |
| Squamous cell carcinoma | 32 (34.8) | 33 (30.6) |
| Large cell | 31 (33.7) | 43 (39.8) |
| Other | 3 (3.3) | 13 (12) |
| Unknown | 13 (14.1) | 9 (8.3) |
| Days of follow-up, mean, median (min–max) | 562, 409 (50–2200) | 600, 548 (43–1500) |
Note: RT1 = radiotherapy planning based on computed tomography; RT2 = radiotherapy planning based on positron emission tomography and computed tomography; WHO = World Health Organization.